Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT05428007 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

105

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Unresectable Melanoma

Interventions

DRUG: Sarilumab
DRUG: Ipilimumab Injection
DRUG: Nivolumab/Relatlimab

Sponsor

NYU Langone Health